CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,000 enrolled
Drug / intervention
Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcomeother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04276025
NCT04276025N/ACompleted
CompareCT.gov

Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer

Klinikum Bayreuth GmbH·observational·Posted Feb 19, 2020·Updated Feb 19, 2020

In Brief

An observational study evaluating Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome for NSCLC. Completed, enrolled 2,000 participants.

Detailed Summary

Retrospective study in patients with therapy-naive non small cell lung carcinoma correlating presurgical F18-FDG-PET/CT imaging texture analysis data with postsurgical molecular pathology data and clinical patient outcome. Main aim is to identify pretherapeutic prognostic factors.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
Countries--
CollaboratorsPeking University Cancer Hospital & Institute, Sana Klinikum Hof

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 19, 2020
Enrollment StartJul 1, 2016
Primary CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.4 years ago

Interventions

Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcomeother

Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.